Krystal Biotech, Inc. (NASDAQ:KRYS) CAO Sells $131,415.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $179.25 on Friday. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34. The company has a 50 day moving average price of $159.41 and a 200 day moving average price of $175.17. The firm has a market capitalization of $5.16 billion, a price-to-earnings ratio of 59.95 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the prior year, the business posted $0.30 earnings per share. Krystal Biotech’s revenue for the quarter was up 116.4% compared to the same quarter last year. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on KRYS. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday. Citigroup upped their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Chardan Capital upped their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech currently has a consensus rating of “Buy” and an average price target of $215.83.

Institutional Investors Weigh In On Krystal Biotech

Several large investors have recently made changes to their positions in KRYS. Creative Planning increased its position in shares of Krystal Biotech by 64.9% in the third quarter. Creative Planning now owns 5,744 shares of the company’s stock worth $1,046,000 after acquiring an additional 2,260 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Krystal Biotech by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,039 shares of the company’s stock valued at $184,000 after purchasing an additional 186 shares in the last quarter. New York State Teachers Retirement System grew its holdings in Krystal Biotech by 6.6% during the 3rd quarter. New York State Teachers Retirement System now owns 15,879 shares of the company’s stock valued at $2,890,000 after purchasing an additional 979 shares in the last quarter. First Trust Direct Indexing L.P. acquired a new stake in Krystal Biotech during the 3rd quarter valued at $252,000. Finally, Janney Montgomery Scott LLC grew its holdings in Krystal Biotech by 17.1% during the 3rd quarter. Janney Montgomery Scott LLC now owns 37,047 shares of the company’s stock valued at $6,744,000 after purchasing an additional 5,415 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).